Did you know? EGFR is a gene found in cells that is important for cell growth and survival. In some people, the EGFR gene begins to mutate or change and may fuse or join with another gene. When this [...]
When Dr. Bryant Lin noticed a persistent cough and an unusual tightness in his throat last spring, he didn’t panic. A busy primary care doctor, clinical professor at Stanford Medicine, and co-director of Stanford’s Center for Asian Health Research [...]
On September 25, 2024, the U.S. Food and Drug Administration (FDA) approved Tagrisso (osimertinib) for people with unresectable stage 3 (III) non-small cell lung cancer (NSCLC). It’s approved for people who have both: Disease that has not progressed during [...]
On September 19, 2024, the U.S. Food and Drug Administration (FDA) issued a new approval for the targeted therapy drug Rybrevant (amivantamab-vmjw) in combination with the existing combination chemotherapy treatment, Paraplatin (carboplatin) + Alimta (pemetrexed). The FDA approved this [...]
WASHINGTON, July 26, 2024 — GO2 for Lung Cancer presented Pasi A. Jӓnne, M.D, Ph.D. with the 2024 Bonnie J. Addario Lectureship Award for his commitment and dedication to research and development of therapeutic strategies for patients with epidermal growth [...]
GO2 for Lung Cancer announced that researchers have described a new familial syndrome in people with lung cancer caused by an inherited gene mutation. The research study was published this month in the Journal of Clinical Oncology. The report chronicles [...]
Question: My tumor’s original biopsy showed that I had non-small cell lung cancer with an EGFR biomarker. Recently, the cancer started progressing and my most recent biopsy shows that I have transformed small cell lung cancer. What does this [...]
Author: Andrew Ciupek, PhD, Associate Director, Clinical Research Targeted therapy research was front and center at the 2022 American Society of Clinical Oncology (ASCO) Annual Meeting. Data was presented from several studies detailing new targeted therapies and better understanding [...]
Author: Daniel A. Saez, MSc, Manager, LungMATCH Navigation Program, GO2 for Lung Cancer People with lung cancer receiving treatment may encounter acquired drug resistance—a reduction in treatment effectiveness over time. Tagrisso (osimertinib) is currently a frontline treatment for people [...]
JoAnn Berridge was misdiagnosed, repeatedly. Doctors thought she had allergy-related post-nasal drip; then they thought she had acid reflux. After a year of trial and error and a persistent cough, her primary care physician ordered a chest X-ray in [...]